Amgen will acquire Horizon Therapeutics, which focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion.

Was this article helpful?
YesNo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Close Search Window